Description

Technical Parameters

Introduction

Stanozolol SuspensionStanozolol2

musclepic 3

Products Description

Stanozolol's primary medical use includes the treatment of hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of severe swelling of the face, limbs, genitals, intestines, and throat. The drug reduces the frequency and severity of HAE attacks by inhibiting the C1-inhibitor deficiency in the complement system. Additionally, it is used in veterinary medicine to promote weight gain, improve appetite, and enhance vitality in animals, such as dogs, cats, and horses. However, in non-medical settings, particularly bodybuilding and competitive sports, stanozolol is favored for its unique effects on muscle tone, strength, and endurance, despite its use being strictly prohibited by the World Anti-Doping Agency (WADA).

## Category 1: Chemical Structure and Synthesis

### Chemical Structure Overview

Stanozolol has a molecular formula of C21H32N2O and a molecular weight of 344.5 g/mol. Its systematic IUPAC name is (1S,4R,5S)-5-(1H-pyrazol-1-yl)-1-methyl-3-oxoandrostan-17β-ol, more commonly known as 17α-methyl-5α-androstane-3,2-c-pyrazole-17β-ol. The structure is derived from dihydrotestosterone (DHT), but with key modifications: the introduction of a 17α-methyl group to enhance oral bioavailability, and the formation of pyrazole rings at the 3- and 2-positions, which impart unique anabolic properties.

The introduction of the pyrazole ring is a key feature that distinguishes Stanozolol from other AAS. It stabilizes the molecule, reduces first-pass metabolism in the liver, and reduces its aromatization propensity, meaning it is not converted to estrogen. This is in stark contrast to traditional testosterone derivatives, which often lead to water retention and estrogen-related side effects. Stanozolol's stereochemical configuration is in the 5α-reduced form, ensuring its affinity for the androgen receptor is approximately one-third that of testosterone, yet its anabolic index is three times that of testosterone.

### Synthesis Route

The industrial synthesis of stanozolol begins with DHT. First, the 17-hydroxyl group of DHT is converted to a methyl ether intermediate via a 17α-methylation reaction using a methylating agent such as methyl iodide and a basic catalyst. Subsequently, a pyrazole ring is introduced at the 3-keto position. This involves a condensation reaction with hydrazine to form a pyrazoline intermediate, which is then stabilized by an oxidation step (e.g., using potassium manganate). Finally, the 17β-hydroxyl group is restored to activity via hydrolysis. This process must be performed under an inert atmosphere to avoid oxidative degradation, resulting in a yield exceeding 80%.

To prepare the oil suspension, pure stanozolol powder (≥99% purity) is mixed with a carrier oil (such as cottonseed oil or sesame oil) to form a microcrystalline suspension. A 50mg/ml concentration means each ml contains 50 mg of active ingredient, resulting in a total of 500 mg of drug in a 10ml vial. This oil-based formulation differs from traditional aqueous suspensions, which can be painful at the injection site. The oil-based formulation provides a smoother release profile.

### Structure-Activity Relationship (SAR) Studies of Stanozolol have shown that the pyrazole ring enhances binding affinity to the androgen receptor (AR) while reducing affinity for sex hormone-binding globulin (SHBG) to only 5% that of testosterone. 17α-Methylation improves liver stability but also increases the risk of hepatotoxicity. These structural features distinguish Stanozolol from non-aromatized AASs, making it suitable for cutting cycles rather than bulking phases.

## Category 2: Physicochemical Properties

### Physical Properties

Stanozolol is a white to slightly yellow crystalline powder with a fine particle size, making it easy to suspend. Its melting point is approximately 235-241°C, indicating good thermal stability, which is crucial during sterilization processes such as autoclaving. Its density is approximately 1.05 g/cm³, and its logP (octanol-water partition coefficient) is 3.98, indicating moderate lipophilicity, which explains its good solubility in oil-based formulations. However, its solubility in water is extremely low (<0.1 mg/ml), necessitating its suspension.

The viscosity of a 50 mg/ml oil suspension is approximately 5-10 cP (centipoise), similar to light motor oil, ensuring smooth syringeability. Its pH is neutral (approximately 6.5-7.5), making it non-corrosive. Its boiling point is undefined (because it melts before decomposition), but it is stable at room temperature and has a shelf life of over two years when stored at 2-8°C.

### Chemical Properties

Stanozolol is chemically inert and has low sensitivity to light and air, but it degrades to inactive metabolites upon exposure to strong oxidizing agents (such as potassium permanganate). The main reactions include N-oxidation (on the pyrazole ring) and demethylation at the C17 position. Spectroscopic properties: UV absorption peak at 235 nm (ε = 15,000 M⁻¹cm⁻¹), IR spectroscopy shows characteristic peaks at 1730 cm⁻¹ (C=O stretching) and 1600 cm⁻¹ (pyrazole ring). NMR analysis confirmed the chemical shift of the 17β-hydroxy group at 4.2 ppm.

Stability testing showed that stanozolol is highly tolerant to pH fluctuations (4-9) in an oil-based formulation, but polymerization may occur at elevated temperatures (>60°C). Degradation products include 16β-hydroxystanozolol (the primary urinary metabolite), which is used in doping control.

### Interactions with Oil-Based Formulations

The physicochemical properties of oil-based suspensions are influenced by the carrier: the use of medium-chain triglycerides (MCT oil) can reduce viscosity and improve bioavailability. The 50mg/ml concentration ensures a total dose of 500mg per 10ml vial, suitable for a 4-8 week cycle (2-3 injections per week, 25-50mg dose).

## Category 3: Formulations and Appearance

### Formulation Forms

Stanozolol Suspension, 50mg/ml, 10ml oil, is a sterile injectable suspension packaged in glass ampoules or multi-dose vials. Unlike aqueous-based formulations (which can crystallize and cause pain), this oil-based version uses a vegetable oil, such as grapeseed oil, as a carrier and contains benzyl alcohol (0.9%) as a preservative. The formulation process involves high-speed homogenization to disperse Stanozolol microcrystals into the oil phase, with a controlled particle size of 5-10 μm to ensure uniformity and biocompatibility.

This formulation is designed with a high concentration (50mg/ml), allowing for small injection volumes (0.5-1ml/injection), reducing injection frequency. FDA standards (21 CFR § 522.2150) specify 50 mg of stanozolol per ml for veterinary use, but the dosage for human use is similar.

### Appearance and Color

The product appears as a clear to slightly hazy yellow oily liquid. The color is derived from the inherent hue of stanozolol and the natural yellow color of the oil carrier. Pure oil-based suspensions are light golden yellow and free of precipitation (even after shaking). Dark brown or particulate matter indicates degradation or contamination. Labeling typically involves a clear vial with a white cap and anti-tamper label, and clearly marked volume.

Organoleptic Characteristics: No noticeable odor, greasy to the touch. During storage, protect from light to prevent color darkening.

### Quality Control

The formulation meets USP (United States Pharmacopeia) standards: purity ≥98%, heavy metals <10 ppm, and sterility-negative. Color consistency is measured using a colorimeter (Pantone 123C).

## Category 4: Pharmacology and Mechanism

### Pharmacokinetics

Oral stanozolol has high bioavailability (>90% due to 17α-methylation) and a half-life of 9 hours. The injectable oil-based form has an extended half-life of 24 hours, providing sustained release. It is rapidly absorbed (peak value 1-2 hours after IM injection), with a volume of distribution of 0.6 L/kg, and is primarily albumin-bound (<20%). Metabolism occurs primarily in the liver, where it is oxidized by CYP3A4 to 3'-hydroxy and 16β-hydroxy metabolites, ultimately excreted in the urine as glucuronide conjugates (80%).

At a 50 mg dose, peak plasma concentrations are approximately 10-15 ng/mL, with steady-state occurring 2-3 days after weekly injection.

### Pharmacodynamic Mechanism

Stanozolol activates the androgen receptor (AR), inducing gene transcription, promoting protein synthesis and nitrogen retention. Simultaneously, it lowers SHBG levels (5% affinity), releasing free testosterone and enhancing anabolism. Its non-aromatizing properties prevent estrogen conversion, yet it increases red blood cell production (an erythropoietin-like effect) and improves oxygen transport. Its diuretic effect stems from its antimineralocorticoid activity, reducing water retention.

In HAE, it inhibits kinin release and stabilizes the blood vessel wall.

## Category 5: Advantages and Benefits

### Medical Benefits

In the treatment of HAE, Stanozolol significantly reduces attack frequency (clinical trials have shown a 70% reduction) and elevates C1-INH and C4 levels without interfering with acute attacks. Its low estrogenic potential compared to other AAS makes it suitable for female patients. Furthermore, in studies of COVID-19 complications, it has demonstrated potential anti-inflammatory effects by reducing kinin storms.

In veterinary applications, it promotes weight gain of 15-20% and improves anemia.

### Performance Enhancement Benefits

In bodybuilding, Stanozolol's "dry muscle" effects are unmatched: increasing muscle firmness and vascularity (without water retention), improving strength by 10-15%, and endurance by 20%. Lowering SHBG increases testosterone utilization by 30%, accelerating recovery. The oil-based form provides stable blood concentrations, making it suitable for cutting cycles. Combined with diet, it can reduce fat mass by 5-10% without losing muscle mass.

Compared to other AAS, it has lower hepatotoxicity (although it carries risks) and a rapid onset of action (within one week).

### Other Benefits

Inhibits glucocorticoids and maintains nitrogen balance; increases red blood cells and enhances aerobic capacity. Long-term use can improve bone density and assist in the treatment of osteoporosis.

## Category 6: Clinical Uses, Risks, and Precautions

### Clinical Uses

Medical: HAE starting dose 2 mg/day, maintenance 1 mg/day; injectable form for severe cases. Veterinary: Horses 50 mg IM weekly. Non-medical: 6-8 week cycles, 25-50 mg/day for men, 5-10 mg/day for women.

### Risks and Side Effects

Hepatotoxicity: Jaundice, elevated enzymes (ALT > 3x normal); Cardiovascular: 30-50% decrease in HDL cholesterol, increase in LDL cholesterol. Androgenic: Acne, hair loss, virilization in women. Other: Arthralgia (dry effects), cholesterol imbalance. Rare: Liver tumors, thrombosis.

### Precautions and Regulatory Affairs

Monitor liver function with monthly blood tests. Contraindicated in pregnant women and patients with liver disease. WADA banned substance, with a detection window of 7-10 days (urine metabolites). Store in a cool, dry place, out of reach of children. Do not use without consulting a physician.

## Conclusion

Stanozolol Suspension, 50 mg/ml, 10 ml oil, is a multifaceted compound whose journey from chemical innovation to clinical efficacy embodies the essence of modern drug design. While its benefits are significant, its risks warrant cautious use. Future research may expand its applications in inflammatory and regenerative medicine, but ethical and regulatory challenges remain. This review aims to provide a comprehensive reference to promote responsible use.